Utility of Somatostatin receptor-targeted imaging with Ga-68 DOTATATE PET/MRI in the management of progressive meningiomas

1844Aim: Utility of Somatostatin receptor-targeted imaging with Ga-68 DOTATATE PET/MRI in the management of progressive meningiomas Meningiomas are the most common type of intracranial tumors. Although these brain tumors are generally benign, some of these could be very aggressive which require extensive surgery followed by radiotherapy. Treating such refractory meningiomas could be extremely challenging. Various treatment protocols are in vogue such as cytotoxic chemotherapy and targeted therapies. One such relatively newer targeted therapy option employs sandostatin, a somatostatin analog that specifically targets somatostatin receptors (SSR) that are overly expressed in these tumors. Furthermore, a radioactive version of such a treatment called Peptide receptor radiotherapy with Lu-177 DOTATATE is becoming increasingly popular for such meningiomas outside the United states. As an imaging biomarker to his therapy, Octreoscan imaging has been used in the past to document the avidity of these SSR in such tumors. But with Ga-68 DOTATATE currently replacing Octreoscan nationwide in the NET imaging arena secondary to its excellent imaging characteristics, it would probably be the best to evaluate these recurrent aggressive meningiomas using Ga-68 DOTATATE PET/MRI. We have employed this imaging technique in such brain tumors to document their SSR avidity which in turn greatly helps the neurosurgeons and neurooncologists guide the appropriate treatment in such challenging and aggr...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Technologist Poster Session Source Type: research